Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PCRX
  • CUSIP: 69512710
  • Web:
  • Market Cap: $1.33 billion
  • Outstanding Shares: 40,341,000
Average Prices:
  • 50 Day Moving Avg: $36.37
  • 200 Day Moving Avg: $42.42
  • 52 Week Range: $29.95 - $58.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 35.43
  • P/E Growth: -3.84
Sales & Book Value:
  • Annual Revenue: $281.47 million
  • Price / Sales: 4.72
  • Book Value: $6.47 per share
  • Price / Book: 5.09
  • EBITDA: ($34,940,000.00)
  • Net Margins: -23.36%
  • Return on Equity: -12.44%
  • Return on Assets: -6.07%
  • Debt-to-Equity Ratio: 1.03%
  • Current Ratio: 7.84%
  • Quick Ratio: 7.26%
  • Average Volume: 746,066 shs.
  • Beta: 2.12
  • Short Ratio: 3.68

Frequently Asked Questions for Pacira Pharmaceuticals (NASDAQ:PCRX)

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.06. The firm earned $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business's quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.21 EPS. View Pacira Pharmaceuticals' Earnings History.

When will Pacira Pharmaceuticals make its next earnings announcement?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Pacira Pharmaceuticals.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?

17 equities research analysts have issued 12-month price objectives for Pacira Pharmaceuticals' stock. Their predictions range from $31.00 to $87.00. On average, they expect Pacira Pharmaceuticals' share price to reach $52.62 in the next year. View Analyst Ratings for Pacira Pharmaceuticals.

What are analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt." (10/9/2017)
  • 2. Cowen and Company analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
  • 3. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:

  • David M. Stack, Chairman of the Board, Chief Executive Officer
  • Charles A. Reinhart III, Chief Financial Officer
  • Scott N. Braunstein M.D., Senior Vice President - Strategy and Corporate Development
  • James B. Jones M.D., Senior Vice President, Chief Medical Officer
  • Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary
  • Robert J. Weiland, Chief Commercial Officer
  • Mark Froimson, Director
  • Gary Pace Ph.D., Director
  • Laura A. Brege, Independent Director
  • Yvonne L. Greenstreet M.D., Independent Director

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include HEALTHCOR MANAGEMENT, L.P. (6.20%), POINT72 ASSET MANAGEMENT, L.P. Total Shares: 2,038,882 (5.10%), Mutual of America Capital Management LLC (0.37%), Nationwide Fund Advisors (0.25%) and Mizuho Securities USA LLC (0.02%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Mizuho Securities USA LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC and Nationwide Fund Advisors. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, John P Phd Longenecker, Mark Froimson and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $32.95.

MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  520 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  777
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $52.62 (59.68% upside)
Consensus Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Needham & Company LLCLower Price TargetBuy -> Buy$55.00 -> $52.00N/AView Rating Details
10/13/2017Royal Bank Of CanadaReiterated RatingBuy$54.00N/AView Rating Details
10/4/2017Bank of America CorporationLower Price TargetBuy$46.00 -> $45.00LowView Rating Details
10/1/2017Canaccord GenuityReiterated RatingBuy$48.00 -> $44.00LowView Rating Details
9/28/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$41.00MediumView Rating Details
9/25/2017MizuhoReiterated RatingBuy$53.00MediumView Rating Details
9/7/2017Jefferies Group LLCReiterated RatingBuy$59.00MediumView Rating Details
9/7/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
9/7/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformMediumView Rating Details
8/23/2017WedbushReiterated RatingOutperform$87.00MediumView Rating Details
8/21/2017Janney Montgomery ScottUpgradeSell -> Neutral$31.00LowView Rating Details
8/3/2017BMO Capital MarketsLower Price TargetMarket Perform$42.00 -> $40.00LowView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$59.00MediumView Rating Details
8/2/2017Cowen and CompanyReiterated RatingHoldMediumView Rating Details
3/21/2017Barclays PLCReiterated RatingOverweight -> Overweight$54.00 -> $59.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformHighView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$60.00MediumView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings History by Quarter for Pacira Pharmaceuticals (NASDAQ PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$0.03N/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.11)$73.37 million$70.90 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.25)($0.25)($0.25)
Q3 20171($0.29)($0.29)($0.29)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)


Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Ownership Percentage: 6.60%
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Paul J HastingsDirectorSell1,044$36.15$37,740.60View SEC Filing  
8/15/2017David M StackCEOSell28,885$36.37$1,050,547.45View SEC Filing  
8/15/2017Kristen Marie WilliamsCAOSell3,461$36.75$127,191.75View SEC Filing  
8/8/2017Mark FroimsonDirectorBuy100$37.13$3,713.00View SEC Filing  
6/5/2017David M StackCEOSell4,311$43.32$186,752.52View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.12View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.64View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.76View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.00View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.26View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.00View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pacira Pharmaceuticals (NASDAQ:PCRX)
Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
Loading headlines, please wait.



Pacira Pharmaceuticals (PCRX) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.